{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:15:07Z","timestamp":1782476107184,"version":"3.54.5"},"reference-count":29,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2006,7,7]],"date-time":"2006-07-07T00:00:00Z","timestamp":1152230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Flumazenil is a short\u2010acting intravenously administered \u03b3\u2010aminobutyric acid (GABA) antagonist used to reverse the effects of benzodiazepines. Based upon current basal ganglion models in Parkinson's disease (PD), flumazenil could normalize neuronal signaling at several different locations. We conducted a double\u2010blind, placebo controlled, single dose, cross\u2010over trial of flumazenil and placebo in 16 subjects with PD. Subjects were primarily assessed with serial tapping tests (1 minute for each hand) at 15\u2010minute intervals for 90 minutes after infusion. Secondary assessments included the Unified Parkinson's Disease Rating Scale (UPDRS) Motor part at baseline and 45 minutes after infusion, and global impressions. Subjects then underwent a 90\u2010minute washout and entered the opposite arm of the cross\u2010over. Change in tapping speed compared to baseline improved throughout the 90\u2010minute period (<jats:italic>P<\/jats:italic> &lt; 0.0001) and at each individual time (<jats:italic>P<\/jats:italic> &lt; 0.01), except for 15 minutes status after infusion, with flumazenil compared to placebo. UPDRS scores tended to improve more on drug, but this finding was not significant. The medication was well tolerated. The most common adverse event on drug was a sense of \u201clight\u2010headedness\u201d or \u201cdizziness.\u201d GABA antagonists represent a novel potential treatment class for PD. \u00a9 2006 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.21022","type":"journal-article","created":{"date-parts":[[2006,7,7]],"date-time":"2006-07-07T15:01:53Z","timestamp":1152284513000},"page":"1614-1617","source":"Crossref","is-referenced-by-count":16,"title":["Intravenous flumazenil for Parkinson's disease: A single dose, double blind, placebo controlled, cross\u2010over trial"],"prefix":"10.1002","volume":"21","author":[{"given":"William G.","family":"Ondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz S.","family":"Silay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(00)01646-1"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900009871"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900009895"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/290514a0"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(92)90267-B"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0739"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.1997.tb03692.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03018846"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199142060-00010"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(85)90080-9"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(85)90218-3"},{"key":"e_1_2_6_13_2","first-page":"142","article-title":"Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP\u2010induced parkinsonism","volume":"547","author":"Filion M","year":"1991","journal-title":"Brain Res"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10426"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.3.802"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/119.5.1717"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/297422a0"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02801973"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(88)90179-7"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(77)90071-5"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050262"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(98)00043-4"},{"key":"e_1_2_6_24_2","first-page":"207","volume-title":"Presynaptic receptors","author":"Lloyd KG","year":"1979"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410370611"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320608"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320206"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/120.8.1301"},{"key":"e_1_2_6_29_2","first-page":"244","article-title":"[Evaluation of benzodiazepine receptor in the cerebral cortex of Parkinson's disease using 123I\u2010iomazenil SPECT]","volume":"55","author":"Kawabata K","year":"1997","journal-title":"Nippon Rinsho \u2010 Jpn J Clin Med"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(98)01164-0"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21022","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:27:56Z","timestamp":1760966876000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,7]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1002\/mds.21022"],"URL":"https:\/\/doi.org\/10.1002\/mds.21022","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,7]]}}}